Check out our most popular compounded medications! Get Started
Morphine Sulfate 150 mg Slow Release Capsules are formulated with Methocel E4M, a controlled-release polymer. This design allows for the gradual release of the active ingredient over an extended period, providing sustained therapeutic effects. This formulation is used to treat various types of pain including chronic, cancer, postoperative, neuropathic, and arthritis pain. The slow release mechanism also reduces dosing frequency, thereby improving patient compliance.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Morphine Sulfate 150 mg Slow Release Capsules are a potent, long-acting opioid analgesic designed to manage moderate to severe chronic pain. This unique formulation incorporates Methocel E4M, a type of controlled-release polymer, which ensures a gradual and consistent release of the active ingredient, morphine sulfate, over an extended period. This slow-release mechanism offers sustained therapeutic effects, reducing the need for frequent dosing and enhancing patient compliance, particularly for those requiring a controlled and prolonged release profile for their pain management.
It is crucial to understand that this formulation is not intended for the treatment of acute pain. Its use should be strictly limited to chronic pain management under the supervision of a healthcare professional. Misuse or overuse of this medication can lead to serious health complications, including dependency and addiction. Therefore, it is essential to adhere strictly to the prescribed dosage and duration of treatment.
Patients taking Morphine Sulfate 150 mg Slow Release Capsules should be aware of potential side effects, which may include drowsiness, dizziness, and other symptoms. It is recommended to avoid driving or operating heavy machinery until you know how this medication affects you. If any side effects persist or worsen, seek immediate medical attention.
Healthcare providers prescribing this formulation should closely monitor their patients for signs of misuse or abuse. Regular follow-ups and dose adjustments may be necessary to ensure the safe and appropriate use of this medication. It is also important to educate patients about the potential risks and benefits associated with the use of this medication.
If you have any questions or concerns about Morphine Sulfate 150 mg Slow Release Capsules, please do not hesitate to contact us at Bayview Pharmacy. Our team of compounding pharmacists is committed to providing comprehensive information and support to ensure the safe and appropriate use of our compounded medications.
Morphine Sulfate 150 mg Slow Release Capsules are a potent analgesic medication indicated for the management of moderate to severe pain. These capsules are formulated with Methocel E4M, a type of controlled-release polymer, which allows for the gradual release of the active ingredient over an extended period. This sustained release mechanism offers prolonged therapeutic effects, reduces the frequency of dosing, and enhances patient compliance, particularly for medications that necessitate a controlled and extended release profile.
It is crucial to note that Morphine Sulfate 150 mg Slow Release Capsules should not be administered to patients with known hypersensitivity to morphine or other opioids. Additionally, they should not be used in patients with significant respiratory depression, acute or severe bronchial asthma, or other severe respiratory conditions. Patients on this medication should be closely monitored for signs of opioid toxicity, which may include symptoms such as sedation, confusion, and respiratory depression.
Interactions may occur when Morphine Sulfate 150 mg Slow Release Capsules are taken in conjunction with other medications, including monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, and other opioids. Patients should be closely observed for signs of serotonin syndrome, which may manifest as agitation, confusion, sweating, and changes in heart rate. Furthermore, signs of opioid toxicity, such as sedation, confusion, and respiratory depression, should also be monitored.
Caution is advised when administering Morphine Sulfate 150 mg Slow Release Capsules to patients with renal or hepatic impairment, as well as those with a history of substance abuse or addiction. Regular monitoring for signs of opioid toxicity, including sedation, confusion, and respiratory depression, is recommended in these patients.
Morphine Sulfate 150 mg Slow Release Capsules should not be used in combination with alcohol or other central nervous system depressants, as this may increase the risk of serious adverse effects. Regular monitoring for signs of opioid toxicity, including sedation, confusion, and respiratory depression, is recommended in these patients.
If you have any questions or concerns about the use of Morphine Sulfate 150 mg Slow Release Capsules, please do not hesitate to reach out for further information.
Morphine Sulfate 150 mg Slow Release Capsules are a potent, extended-release opioid medication designed to manage moderate to severe pain. These capsules are formulated with Methocel E4M, a type of controlled-release polymer, which ensures the gradual release of the encapsulated medication over an extended period. This slow-release mechanism provides a consistent level of pain relief, reduces the frequency of dosing, and enhances patient compliance, particularly for medications requiring a controlled and prolonged release profile.
The capsules are administered orally, typically once a day, and should be consumed with food. It is crucial to adhere to the prescribed dosage and frequency as directed by your healthcare provider. Overdosing or frequent intake can lead to adverse effects and potential dependency.
Morphine Sulfate 150 mg Slow Release Capsules are versatile in their application, effectively managing pain in various disease states such as cancer, chronic conditions, post-operative recovery, and end-stage renal disease. The medication functions by binding to opioid receptors in the brain and spinal cord, thereby reducing the perception of pain.
It is essential to be aware of potential side effects, which may include nausea, constipation, dizziness, and drowsiness. If you experience any of these symptoms or have any concerns about the medication, it is recommended to consult with your healthcare provider immediately.
Remember, Morphine Sulfate 150 mg Slow Release Capsules are a powerful medication and should be used responsibly. Always follow your healthcare provider's instructions and reach out if you have any questions or concerns about your treatment.
Morphine Sulfate 150 mg Slow Release Capsules is a medication formulated with Methocel E4M, a type of controlled-release polymer. This formulation is designed to release the encapsulated medication gradually over an extended period of time, offering sustained therapeutic effects.
The controlled-release polymer, Methocel E4M, is designed to release the medication gradually over an extended period of time. This offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance for medications requiring a controlled and prolonged release profile.
Due to the controlled-release nature of this medication, the dosing frequency is typically reduced. However, the exact frequency will depend on your doctor's prescription and your specific medical condition.
Slow-release medications offer several benefits. They provide sustained therapeutic effects over an extended period of time, reduce the frequency of dosing, and improve patient compliance, especially for medications requiring a controlled and prolonged release profile.
The active ingredient in Morphine Sulfate 150 mg Slow Release Capsules is Morphine Sulfate. This is encapsulated within a controlled-release polymer to ensure gradual release over time.
No, Morphine Sulfate 150 mg Slow Release Capsules should not be broken or crushed. Doing so can release all of the drug at once, increasing the risk of morphine overdose.
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
Common side effects may include constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. You should contact your doctor if any of these symptoms persist or worsen.
No, you should not drink alcohol while taking Morphine Sulfate 150 mg Slow Release Capsules. Mixing these substances can lead to dangerous side effects or a fatal overdose.
People with certain medical conditions, such as severe asthma or breathing problems, a blockage in your stomach or intestines, or a hypersensitivity to morphine should not take Morphine Sulfate 150 mg Slow Release Capsules. Always consult your healthcare provider before starting any new medication.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
